EFFECT: A randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer

Laura Biganzoli (laura.biganzoli@uslcentro.toscana.it)
Nuovo Ospedale di Prato S.Stefano

https://orcid.org/0000-0001-7989-8658

Saverio Cinieri
Pirrino Hospital

Rossana Berardi
Ospedali Riuniti di Ancona

Rebecca Pedersini
Hospital Civili di Brescia

Amelia McCartney
Azienda USL Toscana centro Sedi di Prato

Alessandro Marco Minisini
Azienda Sanitaria Universitaria Integrata di Udine

Elena Rota Caremoli
Aziende Socio Sanitarie Territoriale Papa Giovanni XXIII

Simon Spazzapan
IRCCS CRO di Aviano, National Cancer Institute

Emanuela Magnolfi
Hospital Civile SS Trinita di Sora

Antonella Brunello
Veneto Institute of Oncology IOV Padova

Emanuela Risi
Azienda USL Toscana centro Sedi di Prato

Raffaella Palumbo
IRCCS ICS Maugeri, Pavia

Silvana Leo
Vito Fazzi Hospital, Lecce

Marco Colleoni
European Institute of Oncology IRCCS, Milan

Sara Donati
Ospedale Versilia

Sabino De Placido
AOU Federico II, Naples

Laura Orlando
Perrino Hospital
Mirco Pistelli  
Ospedali Riuniti di Ancora  

Veronica Parolin  
Azienda Ospedaliera Universitaria Integrata Verona  

Anna Mislang  
Flinders Medical Centre  

Dimitri Becheri  
Azienda USL Toscana centro Sedi di Prato  

Fabio Puglisi  
Azienda Ospedaliero Universitaria Integrata di Udine  

Giuseppina Sanna  
Azienda USL Toscana centro Sedi di Prato  

Elena Zafarana  
Azienda USL Toscana centro Sedi di Prato  

Luca Boni  
Azienda Ospedaliero Universitaria Careggi  

Giuseppe Mottino  
Azienda USL Toscana centro Sedi di Prato  

---  

Research article  

Keywords: nab-paclitaxel, functional decline, toxicity, breast cancer, older adults, metastatic  

DOI: https://doi.org/10.21203/rs.2.24444/v2  

License: © This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

Background: Limited data are available regarding the use of nab-paclitaxel in older patients with breast cancer. A weekly schedule is recommended, but there is a paucity of evidence regarding the optimal dose. We evaluated the efficacy of two different doses of weekly nab-paclitaxel, with a specific focus on their corresponding impact on patient function, in order to address the lack of data specifically relating to the older population.

Methods: EFFECT is an open-label, phase II trial wherein 160 women with advanced breast cancer aged ≥ 65 years were enrolled from 15 institutions within Italy. Patients were randomly assigned 1:1 to receive nab-paclitaxel 100 mg/m² (Arm A) or 125 mg/m² (Arm B) on days 1,8,15 on a 28-day cycle, as first-line treatment for advanced disease. The primary endpoint was event-free survival (EFS), wherein an event was defined as disease progression (PD), functional decline (FD) or death. In each arm, the null hypothesis that the median EFS would be ≤7 months was tested against a one-sided alternative according to the Brookmeyer Crowley test. Secondary endpoints included objective response rate (ORR), clinical benefit rate (CBR), progression-free survival (PFS), overall survival (OS), and safety.

Results: After a median follow-up of 32.6 months, 140 events were observed in 158 evaluable patients. Median EFS was 8.2 months (90% CI, 5.9-8.9; p=0.188) in Arm A, versus 8.3 months (90% CI, 6.2-9.7; p=0.078) in Arm B. Progression-free survival, overall survival and response rates were similar in both groups. A higher percentage of dose reductions and discontinuations due to adverse events (AEs) was noted in Arm B. The most frequently reported non-hematological AEs were fatigue (grade [G] 2-3 toxicity occurrence in Arm A versus B: 43% and 51%, respectively) and peripheral neuropathy (G2-3 Arm A versus B: 19% and 38%, respectively).

Conclusion: Pre-specified outcomes were similar in both treatment arms. However, 100 mg/m² was significantly better tolerated with fewer neurotoxicity-related events, representing a more feasible dose to be recommended for older patients with advanced disease.

Trial registration

EudraCT identifier: 2012-002707-18, registered June 4 2012 - https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002707-18/IT#E. NIH ClinicalTrials.gov identifier: NCT02783222, registered May 26 2016 – retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT02783222

Background

Older patients are at higher risk of chemotherapy-related toxicities in comparison to younger adults (1). Weekly solvent-based taxanes, such as paclitaxel and docetaxel, are among the recommended agents to treat older patients with advanced breast cancer (ABC) (2). However, close monitoring is required given that treatment-induced side-effects, particularly neurotoxicity and fatigue, place older patients at risk of subsequent functional decline (FD) (3-7). Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) does not require steroid premedication, and is associated with a lower rate of hypersensitivity reactions (8-10), thus representing an efficacious and safe alternative to solvent-based taxanes. Additionally, recovery from nab-paclitaxel-induced neurotoxicity is reputedly shorter than with solvent-based taxanes (8,9), which may subsequently produce a reduction in negative functional impact. Limited data exist regarding the use of nab-paclitaxel in elderly patients, and uncertainty still prevails regarding the ideal dose to be used in this population. A previous post-hoc analysis of two studies investigated the safety and efficacy of q1w and q3w nab-paclitaxel compared with q3w solvent-based paclitaxel and docetaxel in older patients with ABC (11). Two doses of weekly nab-paclitaxel (150mg/m² and 100 mg/m², on days 1,8,15 on a 28-day cycle) were evaluated. Nab-
paclitaxel was found to be safer and more efficacious when administered weekly. However, these conclusions were limited by way of a small studied group: only 24 patients aged ≥65 years were treated with weekly nab-paclitaxel. Additionally, the reported 20% incidence of Grade 3 sensory neuropathy was concerning.

The EFFECT trial aimed to identify the optimal weekly dose of nab-paclitaxel that could be effectively used in older patients with ABC, whilst also integrating geriatric assessment tools to evaluate the impact of treatment on function.

Methods

Study design and conduct

EFFECT (EudraCT 2012-002707, ClinicalTrials.gov identifier: NCT02783222) is an open-label, randomized, phase II study evaluating two doses of weekly nab-paclitaxel as first-line treatment in older women with ABC. Patients were recruited across 15 cancer centres in Italy, with prospective approval of the protocol by local independent ethics committees at each site. Written informed consent was obtained from all patients.

Patients and treatments

Eligible patients were female aged ≥65 years with pathologically confirmed ABC of any hormone-receptor (HR) and HER2 status, and a history of no prior lines of treatment in the advanced setting. In line with the absence of inclusion of anti-HER2 agents in the trial protocol, women with HER2-positive disease were required to have contraindications to their administration. Additional inclusion criteria were Eastern Cooperative Oncology Group (ECOG) performance status 0-2, the presence of measurable or evaluable disease according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), adequate organ function, and an absence of active/symptomatic central nervous system metastases and/or grade ≤1 peripheral neuropathy.

Using an interactive web response system (IWRS) and the minimization algorithm, patients were centrally randomized 1:1 to receive nab-paclitaxel 100mg/m² (Arm A) or 125mg/m² (Arm B) on days 1,8,15 on a 28-day cycle. Patients were stratified according to age (65-74 versus ≥75 years), concomitant diabetes (yes/no), Instrumental Activity of Daily Living (IADL) impairment (yes/no), presence of any grade 3-4 illness according to Cumulative Illness Rating Scale-Geriatric (CIRS-G) score (yes/no), measurable versus evaluable disease, treating centre, and prior exposure to taxanes (yes/no).

Dose modifications for specific treatment-emergent toxicities were mandated by the protocol. Patients continued on trial-assigned treatment until the point of FD, unacceptable toxicity, consent withdrawal, disease progression (PD) or death, or at the discretion of the treating physician.

Study endpoints

The primary study endpoint was event-free survival (EFS), wherein an “event” was either FD, PD or death. FD was defined as a decrease of at least one point from baseline values of activity of daily living (ADLs) and/or instrumental activity of daily living (IADLs) considered by the investigator to be treatment-related and confirmed at subsequent cycle. Secondary endpoints included objective response rate (ORR), clinical benefit rate (CBR), PFS, overall survival (OS) and safety. ORR was defined by the percentage sum of complete responses (CR) and partial responses (PR). CBR was calculated by combining CR, PR and stable disease (SD). ORRs and CBRs were determined only in patients with measurable disease. The calculation of all time-to-event intervals started from the date of randomization. All serious and non-serious adverse events (AEs) were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Both events related, and unrelated to, study treatment were captured.
Assessments

Tumors were evaluated according to RECIST v1.1 within 28 days before randomization and then every 12 weeks until PD. Presence of comorbidities and functional impairments were assessed at baseline using CIRS-G (12), ADL (13) and IADL (14) instruments. ADLs and IADLs were also re-evaluated on day 1 of each cycle. AEs were recorded and graded according to CTCAE version 4.03 and were evaluated by the investigator at every patient visit from baseline until up to 30 days after discontinuation of trial treatment.

Statistical analysis

Efficacy analyses were performed on the modified intention-to-treat population, which included all randomly assigned patients who received at least one dose of the study drug. In each arm, the null hypothesis that the median EFS would be ≤7 months was tested against a one-sided alternative according to the Brookmeyer Crowley test (15). It was estimated that with the enrolment of 144 patients (72 in each arm), every hypothesis test would have a type I error rate of 5% and a power of 90% when the true median EFS was ≥12 months. The distributions of all studied patients according to demographic, clinical, and biologic characteristics and categorical outcomes were summarized as frequencies and percentage. Continuous variables were reported as median and range of variation. The median period of follow-up and its interquartile range were calculated for the entire study cohort according to the reverse Kaplan-Meier method. Distributions of EFS, PFS and OS were estimated using the Kaplan-Meier product-limit method. According to the study design, no formal statistical comparisons between the results observed in the two treatment arms were planned or performed. SAS software version 9.2 (SAS Institute, Cary, NC) was used for the statistical analysis.

During data cleaning, it was observed that some patients had two consecutive reports of G2/3 neurotoxicity or fatigue (which, by CTCAE definition, imply functional impairment of ADLs or IADLs) who were not also reported as having FD. Accordingly, a central review was undertaken. For reports of neurotoxicity, FD was confirmed and recorded in the setting of two consecutive reports of grade 2 or 3 episodes. In the setting of two consecutive reports of grade 2 or 3 fatigue, the responsible investigator was contacted, and FD declared/confirmed only when fatigue was deemed to be treatment-related. The primary study endpoint is subsequently reported both by investigator and by central review.

As there is ongoing and unresolved discussion regarding which age should be used to define “elderly” patients, an unplanned subgroup analysis was also conducted to evaluate major treatment outcomes in patients aged ≥ 75 years.

Results

Between January 2013 and September 2016, 160 patients were accrued and randomized in a 1:1 fashion. Overall, 79 patients per arm were evaluable for efficacy and safety analyses (see CONSORT diagram: Figure 1). The baseline demographics are summarized in Table 1. The median age was 72 years in Arm A and 73 years in Arm B. Overall, approximately 70% were aged ≥70 years and >40% were ≥75 years. The majority of patients had excellent baseline functional status and well-controlled comorbidities.

Treatment Exposure

Overall in both arms, patients received a median of six cycles of nab-paclitaxel. In patients aged 75 and over, those in Arm A completed a median of 6 cycles, with a median of 5 cycles completed by those assigned to Arm B (Table 2). Dose delays were reported in 21% of cycles undertaken in Arm A, and in 23% of cycles in Arm B. More than 70% of patients had dose reductions overall - however, a higher percentage of dose reductions per cycle was noted in Arm B.
The main reasons for treatment discontinuations were (Arm A vs B) PD (53% vs 30%), clinical decision (20% vs 28%), AEs (14% vs 28%), patient choice (9% vs 4%) and FD (2.5% vs 5%).

**Efficacy**

At a median follow-up of 32.6 months (interquartile range, 23.6-41.6), 140 events were observed. The majority of reported events - over 75% in each arm - consisted of PD, with on average only 7% of patients overall experiencing FD (Table 3). The median EFS was 8.2 (90% confidence interval (CI) 5.9-8.9; Brookmeyer-Crowley like test p=0.188) and 8.3 (90% CI 6.2-9.7; Brookmeyer-Crowley like test p=0.078) months for Arms A and B, respectively (Figure 2A). At central review, FD was identified in 17% of patients on average (Table 3), with a consequent comparative reduction in the median EFS by two months in both arms (median EFS 6.2 months versus 6.4 months for Arm A and B, respectively) (Figure 2B). Efficacy outcomes are reported in Table 4.

In patients with measurable disease at baseline (n=125), the ORR was 40% in Arm A and 42% in Arm B, with a CBR of 80% and 69% respectively. In those patients who discontinued nab-paclitaxel in the absence of PD, 27% (n=21) in Arm A and 34% (n=27) in Arm B received a subsequent line of therapy. The median OS in Arm A was 22.4 months (95% CI 17.0-35.6) and 20.7 months (95% CI 16.8-28.6) in Arm B. The main cause of death in both arms was PD (Arm A n=48 [61%]; Arm B n=45 [57%]).

No difference in the distribution of events was observed within the subgroup of patients aged ≥75 years (Table 3). In this group, the median EFS was 8.3 months (90% CI 5.7-8.9) in Arm A and 8.2 (90% CI 3.5-10.9) months in Arm B. Similar outcomes were observed when EFS was evaluated according to age subgroup (data not shown). The median PFS was 8.3 months (95% CI 5.9-10.5) for Arm A and 8.8 months (95% CI 7.4-10.3) for Arm B.

**Safety**

AEs are reported in Table 5, and are consistent with the known safety profile of nab-paclitaxel in the general population. Myelotoxicity was moderate: one patient in Arm A (1%) and three (4%) in Arm B experienced G4 neutropenia. G3 febrile neutropenia was reported in one (1%) and two patients (2.5%) in Arms A and B, respectively. The most frequently reported non-haematological AEs were fatigue and peripheral neuropathy. In Arm B, G2/3 neurotoxicity occurred more frequently (38% vs 19% in Arm A), and with a shorter median time to onset than Arm A. In Arm A, G2 neurotoxicity was reported after a median of 6.5 cycles (range, 2-11), with G3 reported after a median of 6 cycles (range, 3-9). In contrast, G2 neurotoxicity was reported in Arm B after a median of 5 cycles (range, 1-11), with G3 reported after a median of 4.5 cycles (range, 3-8). Severe AEs were reported in ten patients (13%) in each arm. Treatment-related toxicity was reported as the cause of death in three patients: one patient in Arm A died due to acute renal failure secondary to diarrhea; in Arm B, one patient died from complications of severe diarrhea, and another from septic shock secondary to Clostridium difficile infection after a single dose of weekly nab-paclitaxel, on a background of long-term use of corticosteroids and proton pump inhibitors (PPI).

AEs in the patient subgroup aged ≥75 years are reported in Additional File 1: Table S1. Of note, two out of the three Grade 5 toxicities were registered in this age group. The incidence of Grade 2-3 fatigue and neurotoxicity was positively correlated to age in patients treated in Arm B, but not observed in Arm A (Additional File 2: Table S2).

**Discussion**

EFFECT was designed to prospectively identify a dose of nab-paclitaxel that might be safely and efficaciously administered weekly to older women with ABC. Based on the two weekly doses previously evaluated by Gradishar et al
(9) and later explored in a post-hoc analysis which concentrated specifically on the older population (11), 150 mg/m² was not explored as it was considered too toxic for older patients. The studied doses of 100 and 125 mg/m² were chosen based on previous results of a phase II study evaluating these two doses in patients with ABC heavily pre-treated with taxanes, which showed weekly nab-paclitaxel 100 mg/m² (n=75) had similar antitumor activity and more favorable safety profile than 125 mg/m² (n=106) (16). Due to the linear pharmacokinetic of nab-paclitaxel, we considered it worthy to investigate both doses in the first-line setting.

Our study showed that the administration of both doses of nab-paclitaxel were feasible, with comparable median number of delivered cycles in the two arms, but a higher percentage of dose-reduced cycles, and higher rates of treatment discontinuation due to AEs observed in Arm B. The two weekly doses of nab-paclitaxel were equally effective and were associated with similar incidence of FD, noting that the rate of FD increased on the unplanned central review. However, the lower incidence of neurotoxicity observed in Arm A makes 100 mg/m² a more feasible dose in older patients with ABC.

The incidence of neurotoxicity and fatigue are integral concerns related to the administration of taxanes. As maintenance of functional status is fundamental to effective care of the elderly, loss of function was included in the EFS evaluation in this study. As such, EFFECT specifically set an elderly-oriented primary endpoint, wherein EFS was calculated based on the occurrence of an event (PD, FD or death). Central review of data revealed a higher rate of FD than what was initially reported by the investigators, highlighting that FD is commonly under-reported. The explanation for this may be attributed to a lack of familiarity in evaluating FD in clinical trials, as well as FD being a phenomenon that is perhaps under-appreciated in the clinical setting as a whole. It should be noted that due to the restrictive definition set for FD by the study, the increased observation of Grade 2-3 fatigue and neurotoxicity reported in Arm B did not translate into a higher incidence of FD between the two treatment arms.

As expected, fatigue and peripheral neuropathy were the most frequent non-haematological AEs in both arms. Notably, in Arm B, the incidence of Grade 2-3 neuropathy was double than that of Arm A (19% vs 38%). Contrastingly, at 100mg/m², the incidence of Grade 2 and 3 neurotoxicity was 15% and 4%, respectively. These data are comparable with those reported by Gradishar et al in an unselected population (9,10), and equates favourably with those reported by Aapro et al in patients aged ≥ 65 years, treated at the same dose of weekly nab-paclitaxel (21% Grade 3, Grade 2 not reported) (11).

In EFFECT, three deaths were reported as the result of AEs. Diarrhea was associated with the cause of death in all three cases, wherein patients experienced secondary severe dehydration, end-stage renal failure and septic shock. Chemotherapy-associated diarrhea represents a significant event which requires close monitoring and aggressive management in older patients, who are at the highest risk of developing severe and fatal complications from associated dehydration, renal insufficiency, electrolyte imbalance or infection (18, 19). Age and recent antibiotic exposure are well-recognized risk factors for the development of Clostridium difficile infection, as well as the use of PPIs (20) and chemotherapy (21). This may suggest that the concomitant use of PPIs with chemotherapy be made selectively and cautiously in older patients.

EFFECT evaluated weekly nab-paclitaxel specifically in patients aged ≥ 65 years, in order to address this population's under-representation in previous clinical trials. However, a representative subgroup of patients aged ≥ 75 years (n=66) allowed the evaluation of this agent in a strictly defined “older” population. Advanced age did not affect treatment feasibility and efficacy, but was associated with higher incidence of both neurotoxicity and fatigue with the 125mg/m² dose. Notably, two of the three reported deaths occurred in this age subgroup, suggesting a need for closer monitoring of AEs in this potentially less resilient population. The limitations of the unplanned subgroup analysis of
patients aged 75 and over is acknowledged, highlighting the need to conduct prospective trials with adequate power to analyse this particular group of patients. Since the conception and completion of EFFECT, data has been published from a small phase II cohort study (N=40) in patients aged 65 and older receiving 100mg of nab-paclitaxel on days 1, 8 and 15 on a 28-day schedule (17). Fifty-eight percent of those patients had treatment-related toxicities at grade 3 or above, with 30% hospitalised as a consequence. This study was conducted in patients who exhibited a higher incidence of markers of vulnerability at baseline geriatric assessment than in the EFFECT population. This disparity might in part explain the higher incidence of toxicity observed in the former study when compared with the 100 mg/m\(^2\) arm of EFFECT. This further underlines the importance of specifically studying optimal scheduling and dosing in older, vulnerable patient populations.

Reported outcomes in EFFECT were consistent with first-line single agent chemotherapy data in older breast cancer patients (22-24). One of the limitations of this study is that it did not compare the performance of weekly nab-paclitaxel with conventional taxanes, such as solvent-based paclitaxel, which may be seen as the ideal comparator. Two studies have prospectively evaluated paclitaxel 80 mg/m\(^2\) weekly on days 1, 8, and 15 on a 28-day cycle as first-line therapy in small groups of older breast cancer patients (20,21) and found it to be active. However, there were also some significant issues of safety, with one study reporting premature treatment discontinuation in 32% of patients due to fatigue (23), and the other observing toxicity-related treatment interruptions in 15% of patients (5 out of 7 events were due to cardiac toxicity, including two deaths), and Grade 2/3 sensory neurotoxicity in 33% of patients (24).

To our knowledge, this is the first prospective trial evaluating nab-paclitaxel in a numerically robust older population that specifically aims to identify the optimal dose for a population known to be at potential higher risk of treatment-related toxicity. The inclusion of geriatric assessment and the identification of an elderly-related endpoint which included functional decline represent additional strengths of the study. EFS as an endpoint is in line with recommendations generated by the European Organisation for Research and Treatment of Cancer (EORTC) (25), which has advocated for alternative endpoints, such as QoL, toxicity and functional independence to be considered as a way of improving clinical design. The findings of EFFECT improve the evidence base for treating older adults with cancer, which is an area of unmet need identified by the American Society of Clinical Oncology (26).

**Conclusions**

Weekly taxanes are a suitable treatment option for older patients with MBC. While solvent-based paclitaxel and solvent-based docetaxel are established options, the EFFECT trial has evaluated a role of weekly nab-paclitaxel in this selected population, identifying 100 mg/m\(^2\) on days 1,8 and 15 on a 28-day cycle as an effective and well-tolerated dose.

**Declarations**

**Availability of data and materials**

On reasonable request, the data generated and analysed during the current study are available from the corresponding author in accordance with institutional policies.

**Ethics approval and consent to participate**

The study was conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice Guidelines of the Internal Conference on Harmonisation. The protocol and any accompanying material provided to
patients was prospectively approved by the local independent ethics committee at each of the 15 participating sites.

Consent for publication

Not applicable.

Competing interests

DB has received honoraria from Pfizer, Daiichi Sankyo and MDM and research funding from Daiichi Sankyo. RB has undertaken a consulting or advisory role with Otsuka and Boeringher. LBi has received honoraria from Lilly, Novartis and Pfizer, has undertaken a consulting or advisory role with AstraZeneca, Celgene, Daiichi-Sankyo, Eisai, Genomic Health, Ipsen, Lilly, Novartis, Pfizer, Pierre Fabre and Roche; has received research funding (institutional) from Celgene, Genomic Health and Novartis; and has received travel, accommodation or expenses from Celgene, Pfizer, Ipsen and Roche.

AB has undertaken a consulting or advisory role with Eisai, Roche and Eli Lilly, has received research funding from Roche and travel, accommodations or expenses from Eli Lilly and Pharmamar. SC has undertaken a consulting or advisory role with Pierre Fabre, Pfizer, OBI Pharma, Puma Biotechnology, Celldex and AstraZeneca. SDP has received honoraria from Roche, Celgene, GSK, Novartis, Ipsen and AstraZeneca, has undertaken a consulting or advisory role with Roche, Celgene, GSK, Novartis, Ipsen, Lilly, Pfizer and AstraZeneca, has served on speaker's bureau with Roche, Novartis, Lilly, Pfizer, AstraZeneca, Celgene, Eisai and Istituto Gentili, has received research funding from Eisai, Novartis, Roche and AstraZeneca, and travel, accommodation and expenses from Roche, GSK, Novartis, Lilly, Pfizer, Eisai, and AstraZeneca. SD has received travel, accommodation or expenses from Roche, Novartis and Takeda. AMM has undertaken a consulting or advisory role with Novartis, Merck Sharp & Dohme and Pierre Fabre. MP has received honoraria from Celgene, Novartis, Pfizer and Istituto Gentili; has undertaken a consulting or advisory role with Novartis and Sandoz; and received travel, accommodation or expenses from Celgene and Istituto Gentili. FP has received honoraria from Amgen, Eli Lilly, Ipsen, Merck Sharp & Dohme, Roche and Takeda; has undertaken a consulting or advisory role with Eisai, Eli Lilly, Novartis, Pfizer, Pierre Fabre and Roche; has received research funding from AstraZeneca, Eisai and Roche; and received travel, accommodation or expenses from Celgene and Roche. ER has received travel, accommodation or expenses from Pfizer. GS has received honoraria from Novartis; has undertaken a consulting or advisory role with Roche; and has received travel, accommodation or expenses from Eisai, Novartis, Pfizer, Pierre Fabre and Roche. SS has received honoraria from Pfizer and Novartis; has undertaken a consulting or advisory role with Novartis; has received research funding (institution) from Roche, Novartis and Abbott; and travel, accommodations or expenses from Pfizer, Istituto Gentili and Tesaro. All remaining authors declare that they have no competing interests.

Funding

The trial was an academic study sponsored by the not-for-profit foundation “Sandro Pitigliani per la lotta contro i Tumori ONLUS”, and was funded by Celgene through an investigator-initiated research grant. Celgene had no influence on the design or conduct of the trial, and was not involved in the reporting of the data and its interpretation.

Contributions

LBi, GM, FP and LBo were involved in the conception and design of the study. LBi, SC, RB, RPe, AMM, REC, SS, EM, AB, ER, RPa, SL, MC, SD, SDP, LQ, MP, VP, DB, FP, GS, EZ and GM were involved in acquisition of the data (recruited and managed patients, provided facilities). LBo, AMc, AMi and LBi were involved in collection, assembly, analysis and
interpretation of data (eg statistical analysis, biostatistics, computational analysis). All authors were involved in the writing, review and revision of this manuscript. All authors read and approved the final manuscript.

Acknowledgements

The authors would like to thank our patients and their families for their invaluable contributions to the EFFECT study. We thank Daniela Baldari for her role in coordinating study data management.

Abbreviations

**ABC**: Advanced breast cancer

**ADL**: Activity of daily living

**AEs**: Adverse events

**CBR**: Clinical benefit rate

**CIRS-G**: Cumulative Illness Rating Scale – Geriatric

**CR**: Complete response

**EFS**: Event-free survival

**FD**: Functional decline

**G**: Grade

**HR**: Hormone receptor

**IADL**: Instrumental activity of daily living

**ORR**: Objective response rate

**OS**: Overall survival

**PD**: Progressive disease

**PFS**: Progression-free survival

**PR**: Partial response

**Pts**: Patients

**SD**: Stable disease

References

1. van Abbema DL, van den Akker M, Janssen-Heijnen ML, van den Berkmortel F, Hoeben A, de Vos-Geelen J, Buntinx F et al. Patient- and tumor-related predictors of chemotherapy intolerance in older patients with cancer: A systematic review. J Ger Oncol 2019; 10(1):31-41
2. Biganzoli L, Wildiers H, Oakman C, Marotti L, Loibl S, Kunkler I, et al. Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol 2012; 13(4):e148-60.

3. Biganzoli L, Aapro M, Loibl S, Wildiers H, Brain E. Taxanes in the treatment of breast cancer: Have we better defined their role in older patients? A position paper from a SIOG Task Force. Cancer Treat Rev 2016; 43:19-26.

4. Biganzoli L, Licitra S, Moretti E, Pestrin M, Zafarana E, Di Leo A. Taxanes in the elderly: can we gain as much and be less toxic? Crit Rev Oncol Hematol 2009; 70(3):262-71.

5. Lichtman SM, Hurria A, Cirrincione CT, Seidman AD, Winer E, Hudis C, et al. Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840. Ann Oncol 2012; 23(3):632-8.

6. Luciani A, Jacobsen PB, Extermann M, Foa P, Marussi D, Overcash JA, Balducci L. Fatigue and functional dependence in older cancer patients. Am J Clin Oncol. 2008;31(5):424-430. doi:10.1097/COC.0b013e318128d91f

7. Kenis C, Decoster L, Bastin J, et al. Functional decline in older patients with cancer receiving chemotherapy: A multicenter prospective study. J Geriatr Oncol. 2017;8(3):196-205. doi:10.1016/j.jgo.2017.02.010

8. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005; 23(31):7749-803.

9. Gradishar WJ, Krasnojon D, Cheporov S, Makhson AN, Manikhas GM, Clawson A, et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol. 2009; 27(22):3611-9.

10. Liu Y, Ye G, Yan D, Zhang L, Fan F, Feng J. Role of nab-paclitaxel in metastatic breast cancer: a meta-analysis of randomized clinical trials. Oncotarget. 2017; 8(42):72950-8.

11. Aapro M, Tjulandin S, Bhar P, Gradishar W. Weekly nab-paclitaxel is safe and effective in >/=65 years old patients with metastatic breast cancer: a post-hoc analysis. Breast. 2011; 20(5):468-74.

12. Miller MD, Paradis CF, Houck PR, Mazumdar S, Stack JA, Rifai AH, et al. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res 1992; 41(3):237-48.

13. Katz S, Downs TD, Cash HR, Grotz RC. Progress in development of the index of ADL. Gerontologist. 1970; 10(1):20-30.

14. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969; 9(3):179-86.

15. Brookmeyer R, Crowley J. A Confidence Interval for the Median Survival Time. Biometrics. 1982; 38(1):29.

16. Blum JL, Savin MA, Edelman G, Pippen JE, Robert NJ, Geister BV, et al. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer. 2007; 7(11):850-6.

17. Hurria A, Soto-Perez-de-Celis E, Blanchard S, Burhenn P, Yeon CH, Yuan Y et al. A Phase II Trial of Older Adults With Metastatic Breast Cancer Receiving nab-Paclitaxel: Melding the Fields of Geriatrics and Oncology. Clin Breast Cancer. 2019;19(2):89-96. doi:10.1016/j.clbc.2018.10.002

18. Bossi P, Antonuzzo A, Cherny NI, Rosengarten O, Pernot S, Trippa F, et al. Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 2018; 29(Supp 4):iv126-iv142.

19. Network NCC. NCCN Clinical Practice Guidelines in Oncology. Older Adult Oncology. Version 1. 2018. 2018 [Available from: https://www.nccn.org/professionals/physician_gls/pdf/senior.pdf.
20. Trifan A, Stanciu C, Girleanu I, Stoica OC, Singeap AM, Maxim R, et al. Proton pump inhibitors therapy and risk of Clostridium difficile infection: Systematic review and meta-analysis. World J Gastroenterol. 2017; 23(35):6500-15.

21. Neemann K, Freifeld A. Clostridium difficile-associated diarrhea in the oncology patient. J Oncol Pract. 2017; 13(1):25-30.

22. Smorenburg CH, de Groot SM, van Leeuwen-Stok AE, Hamaker ME, Wymenga AN, de Graaf H, et al. A randomized phase III study comparing pegylated liposomal doxorubicin with capcitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG. Ann Oncol 2014; 25(3):599-605.

23. ten Tije AJ, Smorenburg CH, Seynaeve C, Sparreboom A, Schothorst KLC, Kerkhofs LGM, et al. Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial. Eur J Cancer 2004; 40(3):352-7.

24. Del Mastro L, Perrone F, Repetto L, Manzione L, Zagonel V, Fratino L, et al. Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GiOGer). Ann Oncol 2005; 16:253-8.

25. Pallis AG, Ring A, Fortpied C, Penninckx B, Van Nes MC, Wedding U et al. EORTC workshop on clinical trial methodology in older individuals with a diagnosis of solid tumors. Ann Oncol. 2011;22(8):1922-1926. doi:10.1093/annonc/mdq687

26. Hurria A, Levit LA, Dale W, Mohile SG, Muss HB, Fehrenbacher L et al. Improving the Evidence Base for Treating Older Adults With Cancer: American Society of Clinical Oncology Statement. J Clin Oncol. 2015;33(32):3826-3833. doi:10.1200/JCO.2015.63.0319

Tables
Table 1. Baseline characteristics of the ITT population, by treatment arm and age. Reported as n (%) unless otherwise indicated.

| Characteristics         | Arm A (100mg/m²) | Arm B (125mg/m²) |
|-------------------------|------------------|------------------|
|                         | Overall (N=79)   | Patients aged 75+ (N=33) | Overall (N=79) | Patients aged 75+ (N=33) |
| **Median age in years (range)** | 72 (65-84) | 80 (75-84) | 73 (65-88) | 77 (75-88) |
| **Age**                 | 65-69           | 75+             |
|                         | 28 (35)         | 33 (42)         | 21 (27)       | 33 (42)         |
|                         | 72 (65)         | 9 (11)          | 9 (11)        | 9 (11)          |
| **ECOG PS**             | 0               | 1               | 2             | 0               | 1               | 2             |
|                         | 51 (65)         | 19 (24)         | 20 (61)       | 43 (54)         | 19 (58)         | 13 (40)       | 1 (3)         |
|                         | 9 (11)          | 4 (12)          | 9 (27)        | 32 (41)         | 13 (40)         | 13 (40)       | 4 (5)         |
| **ADL scores**          |                 |                 |               |                 |                 |               |
|                         | Impaired        | Missing         | Impaired      | Missing         | Impaired        | Missing         |
|                         | [range]         | data            | [range]       | data            | [range]         | data            |
|                         | 14 (18)         | 2 (2)           | 6 (18)        | 2 (2)           | 20 (25)         | 0               | 8 (24)         | 0               |
|                         | [5/6-4/6]       |                 | [5/6-5/6]     |                 | [5/6-1/6]       |                 | [5/6-1/6]      |                 |
| **IADL scores**         |                 |                 |               |                 |                 |               |
|                         | Impaired        | Missing         | Impaired      | Missing         | Impaired        | Missing         |
|                         | [range]         | data            | [range]       | data            | [range]         | data            |
|                         | 20 (25)         | 2 (2)           | 9 (3)         | 1 (3)           | 20 (25)         | 0               | 8 (24)         | 0               |
|                         | [7/8-2/8]       |                 | [7/8-4/8]     |                 | [7/8-2/8]       |                 | [7/8-3/8]      |                 |
| **Comorbidities**       |                 |                 |               |                 |                 |               |
|                         | Any             |                 |               |                 |                 |               |
|                         | grade 3-4       |                 |               |                 |                 |               |
|                         | 8(10)           | 6 (18)          | 10 (13)       | 3 (9)           |                 |               |
|                         | 9 (11)          | 6 (18)          | 11(14)        | 4 (12)          |                 |               |
| **HR status**           |                 |                 |               |                 |                 |               |
|                         | ER- and         |                 |               |                 |                 |               |
|                         | PgR-            |                 |               |                 |                 |               |
|                         | ER+ and/or      |                 |               |                 |                 |               |
|                         | PgR+            |                 |               |                 |                 |               |
|                         | Missing         |                 |               |                 |                 |               |
|                         | 9 (11)          | 5 (15)          | 8 (10)        | 4 (12)          |
|                         | 68 (86)         | 28 (85)         | 67 (85)       | 28 (85)         |
|                         | 2 (3)           | 0               | 4 (5)         | 1 (3)           |
| **HER2 status**         |                 |                 |               |                 |                 |               |
|                         | Positive        |                 |               |                 |                 |               |
|                         | Missing         |                 |               |                 |                 |               |
|                         | 2 (3)           | 1 (3)           | 0             | 0               |
|                         | 5 (6)           | 2 (6)           | 10 (13)       | 4 (12)          |
| **Prior taxane use**    | 11(14)          | 3 (9)           | 10(13)        | 1 (3)           |
| **Measurable disease**  | 60 (76)         | 22 (67)         | 65 (82)       | 28 (85)         |
| **Visceral disease**    | 56 (71)         | 22 (67)         | 55 (69)       | 25 (76)         |

**Abbreviations:** ADL: activities of daily living; ECOG PS: Eastern Cooperative Oncology Group Performance Status; IADL: instrumental ADL; +, positive; -, negative
| Regimen received | Arm A 100mg/m² | Arm B 125mg/m² |
|------------------|----------------|----------------|
|                  | All (N=79)     | Pts aged 75+   |
| Total n of cycles| 594            | 214            |
| Median n cycles (range) | 6 (1-28) | 6 (1-19) | 6 (1-22) | 5 (1-11) |
| Dose delays      |                |                |
| N of patients    | 52 (66)        | 19 (58)        |
| N of cycles      | 127 (21)       | 43 (20)        |
| Dose reductions  |                |                |
| N of patients    | 57 (72)        | 22 (68)        |
| N of cycles      | 234 (39)       | 78 (36)        |

**Table 2:** Treatment exposure, described by randomized arm, as well as within the subgroup aged ≥75. Reported as n (%) unless otherwise stated.

| Event                      | Arm A 100mg/m² | Arm B 125mg/m² |
|----------------------------|----------------|----------------|
|                            | All (N=79)     | Pts aged 75+   |
| INVESTIGATOR REPORTED      |                |                |
| Pts with reported event    | 69 (87)        | 31 (94)        |
| PD                         | 61 (77)        | 28 (85)        |
| FD                         | 4 (5)          | 1 (3)          |
| Death                      | 4 (5)          | 2 (6)          |
| CENTRAL REVIEW             |                |                |
| Pts with reported event    | 72 (91)        | 32 (97)        |
| PD                         | 56 (71)        | 25 (76)        |
| FD                         | 13 (16)        | 6 (18)         |
| Death                      | 3 (4)          | 1 (3)          |

**Table 3:** Primary endpoint-related events in the overall population and in patients aged 75 years and older. Reported as N (%) unless otherwise indicated.

Abbreviations: FD, functional decline; PD, disease progression; Pts, patients

| Event                      | Arm A 100mg/m² | Arm B 125mg/m² |
|----------------------------|----------------|----------------|
| Median EFS, mos (90% CI)   | 8.2 (5.9-8.9)  | 8.3 (6.2-9.7)  |
| Median EFS pts 75+, mos (90% CI) | 8.3 (5.7-8.9) | 8.2 (3.5-10.9) |
| Median PFS, mos (95% CI)   | 8.3 (5.9-10.5) | 8.8 (7.4-10.3) |
| Median OS, mos (95% CI)    | 22.4 (17.0-35.6) | 20.7 (16.8-28.6) |
| Best overall response*, n(%)| n=60           | n=65           |
| CR                         | 4 (7)          | 1 (2)          |
| PR                         | 20 (33)        | 26 (40)        |
| SD                         | 24 (40)        | 18 (28)        |
| PD                         | 9 (15)         | 14 (21)        |
| NE                         | 3 (5)          | 6 (9)          |

*Based on central review
*Patients with measurable disease
Table 4: Efficacy outcomes, reported by arm
Abbreviations: CI, confidence interval; CR, complete response; EFS, event-free survival; mos, months; NE, not evaluable; OS, overall survival; PFS, progression-free survival; PD, progressive disease; PR, partial response; SD, stable disease

Figures

Figure 1

CONSORT diagram illustrating disposition to treatment arms, plus reasons for discontinuing treatment on trial.
| Follow-up, mos |
|---------------|
|               |
| NAB-PACLITAXEL 100 | 79 | 43 | 22 | 11 | 8 | 5 | 3 | 0 | 0 |
| NAB-PACLITAXEL 125 | 79 | 45 | 18 | 8 | 6 | 4 | 2 | 1 | 0 |

Figure 2

Kaplan–Meier analysis of event-free survival by treatment arm: investigator reported (A), and at central review (B).